Systems, procedure packs and reusable surgical instruments under UK medical device rules

1. Key takeaways

Systems and procedure packs are governed separately by reg 14 and must complete registration before they can be placed on the Great Britain market. In the CE transition context, systems and procedure packs are subject to reg 19B(7), and SI 2023/627 reg 6(5) added a new exclusion: where a procedure pack contains a former-directives Class I device that requires no notified body involvement either under the directives or under EU MDR, the transition does not apply to that pack. Reusable surgical instruments have a dedicated channel of their own within the CE transition.

The combined effect is that a procedure pack cannot be assessed at the pack level alone. Its transition eligibility is inherited from its components, its conformity obligations are those of the person who assembles it, and its registration is its own filing. A pack whose individual components are all perfectly compliant can still lose its route into Great Britain because of a single component that satisfies the exclusion test, which is why component-level record keeping is not optional for this category.

Registration is the second half of the story. Because reg 14 subjects systems and procedure packs to their own registration duty before placing, a pack that is eligible for the transition is still not placeable until its registration is in order. In practice the two tracks are handled by different teams: the regulatory team assesses eligibility while the registration team files in DORS, and the file that proves eligibility is not automatically the file the registration rests on. Keeping both tracks in one project plan, with the registration flagged as a hard predecessor of any shipment, closes the gap between a lawful product and a placeable one.

2. Legal basis

• UK MDR 2002 (SI 2002/618, as amended): reg 14 (procedures for systems and procedure packs, and devices sterilised before use), reg 19B(7).
• SI 2023/627 reg 6(5): inserts new subparagraphs (ba), (bb) and (e) into reg 19B(7).
• Official guidance: the GOV.UK documents titled ‘Register medical devices to place on the market’ and ‘Timelines for acceptance of CE marked medical devices in Great Britain (GB)’.

3. Expert insights

Insight one: compliance of a system or procedure pack is the compliance of a combination. Reg 14 does not deal with one device but with a combination of devices. The legal consequence of combining is that the person who assembles the combination becomes responsible for the compatibility of the components, the sterility state of the combination, and the overall conformity of what results. This responsibility structure differs materially from that of a single-device manufacturer, because the assembler may not have designed any of the components and yet answers for their interaction. Contracts with component suppliers should therefore anticipate the evidence the assembler will need, rather than assuming standard certificates suffice.

Insight two: transition eligibility is dragged down by the weakest component. The exclusion rule in reg 19B(7)(e) means that if a procedure pack contains even one former-directives Class I device that needs no notified body under the directives and none under EU MDR, the entire pack loses its transition eligibility. This is the trap most easily stepped on with combination products, because the offending component is often a trivial accessory that nobody flagged during the transition review. The lesson is procedural: eligibility testing must run over the full bill of materials of every pack, not over the headline components.

Insight three: reusable surgical instruments have a dedicated channel. The official guidance records that a Class I device self-declared under EU MDD before 26 May 2021, where EU MDD required no notified body involvement but EU MDR does, including upclassified devices and reusable surgical instruments, may be placed on the market until 30 June 2028. For hospitals and instrument suppliers this dedicated channel is the difference between continuity and a supply gap, and it should be verified against the declaration date on the signed original, since the 26 May 2021 anchor is a hard eligibility condition rather than a soft guidance point.

For suppliers serving hospital customers, the reusable instrument channel also has a commercial dimension. Tenders and framework agreements signed on the assumption of indefinite CE availability should be reviewed against the 30 June 2028 cut-off, and any supply commitments that outlive it should be renegotiated or re-based on a UKCA or MDR footing while there is still time to complete an assessment. A contract review of this kind is cheap to run early and expensive to run once customers begin asking why deliveries of a compliant-looking product are at risk.

4. Practical recommendations

GRZAN recommends building a component-level compliance ledger for every system and procedure pack: each component is recorded with its classification, the law it rests on, its certificate status and its transition eligibility, and the pack’s own transition eligibility is then derived from the ledger rather than re-argued each time. For packs containing former-directives Class I components, the reg 19B(7)(e) exclusion test should be applied to each component individually and the result recorded, so that any future change of a component, however minor it appears, triggers a documented re-test before the pack ships.

The ledger should also carry the reg 14 procedure evidence: the compatibility assessment, the sterility determinations and the overall conformity statement for the combination. Keeping that evidence alongside the component records means a registration audit or an MHRA information request can be answered from one file, instead of reconstructing the assembly rationale years later from emails and archived drawings.

5. Verification checklist

• □ The reg 14 procedural requirements for systems and procedure packs have been completed
• □ MHRA registration has been completed
• □ A classification and certificate status ledger exists for all components
• □ The reg 19B(7)(e) exclusion test has been applied to each component
• □ The applicability of the dedicated channel for reusable surgical instruments has been confirmed

Regulatory information verified as of 29 October 2026.

• Appointment of a UK responsible person (UKRP) and support for signing the letter of authorisation
• MHRA registration (DORS): end-to-end filing and account lifecycle management
• Device classification, GMDN code selection and annual registration fee estimates
• Dual-route design for Great Britain and Northern Ireland, including UK(NI) options
• Post-market surveillance (PMS) system build, PMSR/PSUR preparation and vigilance reporting
• Emergency handling of serious incidents and field safety corrective actions (FSCA)
• Monitoring of UK regulatory change and compliance gap assessments

GRZAN supports manufacturers entering the United Kingdom with UKCA registration pathways and classification strategy, from first route analysis through to registration and post-market obligations. For a structured review of your product portfolio, contact info@grzanglobal.com.